News and Trends 30 Jun 2023
FDA approves BioMarin gene therapy for hemophilia A
BioMarin Pharmaceutical Inc. has announced that the United States Food and Drug Administration (FDA) has approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of adults with severe hemophilia A…